Skip to contentpdufa.bio

barzolvolimab Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

barzolvolimab Phase is a Celldex Therapeutics, Inc. program in atopic dermatitis. Its next catalyst is a Readout in Q4 2026.

CLDX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Atopic dermatitis. Sponsor: Celldex Therapeutics, Inc. (CLDX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026CLDX

Specialist biotech funds holding CLDX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Baker Bros. Advisors2,564,984$83.1 millionfiled November 16, 2026
OrbiMed Advisors505,000$16.4 millionfiled November 16, 2026
Redmile Group321,770$10.4 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is barzolvolimab Phase's next FDA decision or readout?

The next tracked catalyst for barzolvolimab Phase is a Readout in Q4 2026.

What happened at barzolvolimab Phase's most recent FDA decision?

No FDA decision for barzolvolimab Phase is in our archive yet.

What is barzolvolimab Phase used for?

In our records barzolvolimab Phase is under review or in development for Atopic dermatitis.

Who makes barzolvolimab Phase?

Celldex Therapeutics, Inc. (CLDX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.